

Asthma severity and genetics in Taiwan

Jing-Long Huang

Division of Allergy, Asthma and Rheumatology, Department of Pediatrics, Chang Gung Children's Hospital and Chang Gung University, Taoyuan, Taiwan

Received: May 19, 2004 Revised: May 24, 2004 Accepted: May 26, 2004

The prevalence of childhood asthma in Taiwan has increased dramatically during the last 2 to 3 decades. In Taipei city, the prevalence of asthma in schoolchildren has increased from 1.3% in 1974 to 19.0% in 2003. Genetic mapping and candidate gene analyses have revealed suggestive evidence for linkage of asthma to a number of different chromosomal regions and for association with several candidate genes. Over 70 variants in candidate genes have been reported to be associated with these phenotypes. The main regions these variants have been found are on chromosomes 2q, 5q, 6p, 11q, 12q, 16q and 17q. Five potential asthma susceptibility genes or complexes have been identified using a positional approach. These are A desintegrin and metalloproteinase 33 (ADAM33), dipeptidyl peptidase 10 (DPP10), plant homeodomain zinc finger protein 11 (PHF11) and SET domain, bifurcated 2, G-protein related receptor for asthma (GPRA) and serine protease inhibitor Kazal type 5 (SPINK5). It is also evident that environmental factors will influence the expression of genes and the ultimate clinical phenotype of asthma and atopy. Evidence for a genetic contribution to risk for fatal or near-fatal asthma in Caucasians and Taiwanese has been suggested. We have revealed that the regulation upon activation, normal T cell expressed and secreted (RANTES)-28C/G polymorphism exacerbates asthma severity and represents a genetic risk factor for life-threatening asthma attacks in Chinese children. Moreover, in the Chinese children the frequency of the chemoattractant receptor-homologous molecule expressed on T helper 2 cells (CRTH2) 1651G allele in near-fatal asthmatics was significantly higher than in mild-to-moderate asthmatics and normal controls. The CRTH2 1651G allele of single nucleotide polymorphism rs545659 was also associated with a higher degree of bronchial hyperresponsiveness.

Key words: Asthma, gene expression regulation, genetic markers, genetic polymorphism, genetic predisposition to disease

The prevalence and severity of asthma have been increasing in many countries, the trends being most pronounced for children and adolescents [1]. For example, the prevalence of childhood asthma in Taiwan has increased dramatically during the last 2 to 3 decades. A series of surveys has been conducted in Taiwan over a 30-year period (1974-2003), with current asthma prevalence assessed for children of the same age at the same schools through use of the same method [2,3]. The results showed that the prevalence of asthma in schoolchildren has increased from 1.3% in 1974 to 19.0% in 2003 in Taipei city. Our recent work also indicates that the severity of asthma seems to have increased, as reflected by a significant upward trend in admission rates for cases of childhood asthma in 1 medical center [3]. Thus, childhood asthma is currently a major health problem, not only in western countries but also in Taiwan.

The majority of bronchial asthma in childhood is atopic, with manifestations of allergic diathesis including asthma, rhinitis and eczema and sensitized to inhalant or food allergens. There is also strong evidence for a genetic component in asthma [4-6]. However, multiple environmental factors are also known to modulate the clinical expression of asthma, as well as the asthma-associated phenotypes — airway hyperresponsiveness (AHR), atopy and elevated immunoglobulin E (IgE) [7-9]. It is a commonly held view that asthma is caused by multiple interacting genes, some having a protective effect and others contributing to the disease pathogenesis, with each gene having its own tendency to interact with and be influenced by the environment [7-11]. Thus, the complex nature of the asthma phenotype, together with substantial locus heterogeneity and environmental influence, have made it difficult to uncover the genetic factors that underlie asthma.

The genetics of atopy and asthma are now being characterized using gene discovery and functional genetic methodologies. Susceptibility genes for asthma

*Corresponding author: Dr. Jing-Long Huang, Department of Pediatrics, Chang Gung Children's Hospital, 5, Fu-Hsin Street, Kweishan, Taoyuan, Taiwan.
E-mail: long@adm.cgmh.org.tw*

remain to be defined. Genetic mapping and candidate gene analyses have revealed suggestive evidence for linkage to a number of different chromosomal regions and for association with several candidate genes. Because of the complexity of these conditions, and confounding gene-gene and gene-environmental interactions, characterization of candidate asthma and atopy genes and their products, either in terms of their expression (using single nucleotide polymorphisms [SNPs] and microarrays) or protein function, has been successful to only a limited extent [12,13].

There is evidence that genetic liability for asthma, AHR and allergic traits are regulated through distinct loci, although there is likely some shared overlap as well [14]. The candidate and genome screen approaches have both been used to clarify the roles of genetic factors in the pathogenesis of asthma. A variety of genetic susceptibility loci have been suggested using the candidate gene approach. Many regions of the genome have been found to have linkage with the phenotypes of asthma and atopy. Over 70 variants in candidate genes have been reported to be associated with these phenotypes. The main regions these variants have been found are on chromosomes 2q, 5q, 6p, 11q, 12q, 16q and 17q. Specifically, these include: (1) chromosome 5 in the area of the cytokine gene cluster; (2) chromosome 6 in the area of human leucocyte antigen and tumor necrosis factor genes; (3) chromosome 11 in the area of the high-affinity receptor (Fc γ RI) gene; (4) chromosome 12 in the areas of interferon- γ , insulin-like growth factor-1, β -subunit nuclear factor, and mast cell growth factor genes; (5) chromosome 14 in the area of T cell receptor gene; and (6) chromosome 16 in the area of the interleukin (IL)-4R gene [12]. The severity of asthma and response to treatment have also been suggested to be dependent on genetic modulators, such as the polymorphism of the β_2 -receptor (found on chromosome 5), which is involved in the bronchodilator response to β -agonists [15,16].

Five potential asthma susceptibility genes or complexes have been identified using a positional approach. These are A desintegrin and metalloproteinase 33 (ADAM33), dipeptidyl peptidase 10 (DPP10), plant homeodomain zinc finger protein 11 (PHF11) and SET domain, bifurcated 2, G-protein related receptor for asthma (GPRA) and serine protease inhibitor Kazal type 5 (SPINK5). It is evident that environmental factors will influence the expression of genes and the ultimate clinical phenotype of asthma and atopy. In 2002, Van Eerdewegh et al reported the fine mapping of the

ADAM33 as an asthma and AHR gene on chromosome 20p13 [17], using genome-wide scan from 460 Caucasian families.

A survey of 35 SNPs in 23 genes showed that the ADAM33 variants might directly impact lung architecture and function [17,18]. Although subsequent to the report of Van Eerdewegh et al, other groups have tested ADAM33 SNPs in their asthma cohorts with mixed results. Raby et al [19] did not demonstrate the association of ADAM33 SNPs with asthma or airway responsiveness, and only weak associations were observed with IgE levels and total eosinophilia. Further work needs to be performed both in terms of replication of genetic association and determination of gene function before any firm conclusions can be made regarding the importance of ADAM33 in asthma.

Genetic linkage of asthma and atopy to chromosome 13q14 is one of the most consistent linkage findings and has been replicated in many different populations [9,20,21]. Zhang and coworkers [22] assessed linkage disequilibrium patterns around the marker using densely spaced SNPs, and in parallel studied the gene content of the segment. Evidence for association with total IgE was identified with variants in 2 adjacent blocks, and centered on 1 gene — PHF11 gene. Furthermore, using a stepwise analytic procedure, some studies revealed that 3 polymorphisms localized to PHF11 carried the bulk of the association with IgE: 2 were intronic, and 1 was in the 3'-untranslated region of PHF11 [22-25]. The precise function of this gene has not been determined but the presence of 2 zinc finger motifs in the translated protein suggests a role in the regulation of lymphocyte activation and immunoglobulin synthesis [26].

Repeated genome scans for asthma have implicated a broad peak of linkage on chromosome 2q14-q32 [9, 10]. Allen et al [27] studied the localization of the putative gene by genetic association method, and found association of the microsatellite D2S308 with asthma. The gene, named DPP10, belongs to the conserved family of dipeptidyl peptidases that can cleave off terminal dipeptides from chemokines and cytokines, and might regulate their activities. The functional properties of DPP10 still need further clarification.

There has been recognition of a group of asthmatic patients who suffer from severe and life-threatening asthmatic attacks and in whom high doses of steroids, frequent hospitalization and occasional intubation and ventilation are required. Evidence for a genetic contribution to risk for fatal or near-fatal asthma in Caucasians and Taiwanese has been suggested [28-44].

Table 1. Genotype and allele frequencies of regulation upon activation, normal T cell expressed and secreted (RANTES)-28C/G for asthmatics, atopics and normal controls of Chinese children^a

Group	n	Genotype			Allele frequency (%)	OR (95% CI)	p
		C/C	C/G	G/G	G		
Near-fatal asthma	48	26 (54.2%)	18 (37.5%)	4 (8.3%)	27.1	2.926 (1.414-6.055)	0.006
Mild-to-moderate asthma	134	108 (80.6%)	21 (15.7%)	5 (3.7%)	11.6	0.833 (0.446-1.554)	0.677
Atopic non-asthmatic	69	55 (79.7%)	14 (20.3%)	0 (0%)	10.1	0.880 (0.419-1.849)	0.881
Control	107	83 (77.6%)	23 (21.5%)	1 (0.9%)	11.7	1.0	-

Abbreviations: OR = odds ratio; CI = confidence interval

^aModified from Yao et al [32].

The RANTES (regulated upon activation, normal T cell expressed and secreted) gene lies on chromosome 17q11.2-q12, a region for which linkage to asthma or atopy has been demonstrated in several studies [24,29, 30]. RANTES can produce chemotaxis and activation of inflammatory cells (eosinophils, monocytes, basophils and T cells) that are central to the airway inflammation characteristic of asthma [31]. After evaluation of RANTES SNPs of 48 patients with near-fatal asthma and 134 children with milder asthma, we reported that the RANTES-28C/G polymorphism exacerbates asthma severity and represents a genetic risk factor for life-threatening asthma attacks in Chinese children [32]. The odds ratio for the risk of asthma characterized by near-fatal incidents rather than the mild-to-moderate variant was 3.52 for children with the RANTES-28G allele versus those with the frequently occurring -28C/C genotype (Table 1). The RANTES-28G allele was also associated with an increased eosinophil level and a higher degree of AHR.

Monocyte chemoattractant protein 1 (MCP-1), one of the CC chemokines, appears to play a significant role in asthma pathogenesis because of its ability to attract monocytes, eosinophils, and activate mast cells and basophils, inducing leukotriene C4 release into the airway, thus directly inducing AHR [33,34]. It has been demonstrated that the levels of MCP-1 are increased in the bronchoalveolar lavage fluid of ventilated subjects with status asthmaticus compared with mild-to-moderate asthmatics [35], suggesting that this chemokine may be an important factor in life-threatening asthma attacks.

It has been suggested, however, that there are significant interethnic differences in the allele frequencies for asthma-predisposition genotypes between Asian and Caucasian populations [36]. A polymorphism in the MCP-1 gene regulatory region has been associated with asthma. The MCP-1 gene also lies on chromosome 17q11.2 [37], a region for which linkage to asthma or atopy has

been demonstrated in several Caucasian studies [11, 24,30]. On the contrary, our study demonstrated that the presence of the MCP-1-2518G allele is not a risk factor for near-fatal asthma in the Taiwanese population [38]. Additionally, this study found no association of the -2518A/G polymorphism in the distal gene regulatory region of MCP-1 with asthma susceptibility or severity. This variation may contribute to the pathogenesis of asthma and must be considered in gene-association studies in different ethnic populations.

The chemoattractant receptor-homologous molecule expressed on T helper 2 cells (CRTH2) gene, located within the peak linkage region for asthma on chromosome 11q, encodes a G protein-coupled chemoattractant receptor selectively on Th2 cells, basophils and eosinophils [39-41], and is a novel receptor for prostaglandin, an important mediator in the regulation of inflammatory responses. In addition, CRTH2 has been implicated in the regulation of allergic inflammation [42]. Recently, we also identified a SNPs of the CRTH2 gene by sequencing analyses of genomic DNA samples from a Chinese population [43]. Two SNPs (SNP#1 and #2) with a G to C and an A to G substitution at position 1544 and 1651, respectively, were identified in the 3'-region.

Furthermore, our study suggested significant association of CRTH2 1544G-1651G haplotype with asthma under population-based case-control analyses which were conducted in Chinese and Caucasian populations (Table 2). Moreover, in the Chinese children the frequency of the 1651G allele in near-fatal asthmatics was significantly higher than in mild-to-moderate asthmatics ($p=0.0001$) and normal controls ($p<0.0001$). The 1651G allele of SNP re545659 was also associated with a higher degree of bronchial hyperresponsiveness ($p<0.027$). Moreover, transcriptional pulsing experiments showed that the 1544G-1651G haplotype confers a significantly higher level of reporter mRNA stability when compared with a non-transmitted haplotype,

Table 2. Association analysis of chemoattractant receptor-homologous molecule expressed on T helper 2 cells alleles in the Chinese case-control data^a

SNP	Allele/genotype	Cases n (%)	Controls n (%)	OR (95% CI)	<i>p</i>
1544	G	245 (90.7)	115 (96.6)	0.340 (0.116-1.002)	0.043
	C	25 (9.3)	4 (3.4)		
	GG	113 (83.7)	55 (93.2)		
	GC	19 (14.1)	4 (6.8)		
	CC	3 (2.2)	0		
1651	G	214 (79.3)	58 (50.9)	3.690 (2.305-5.906)	<0.001
	A	56 (20.7)	56 (49.1)		
	GG	88 (65.2)	18 (31.6)		
	GA	38 (28.1)	22 (38.6)		
	AA	9 (6.7)	17 (29.8)		
	Haplotype	Cases (%)	Controls (%)	<i>p</i>	
1544-1651	G-A	12.5	45.6	<0.001	
	C-A	8.7	3.5	0.076	
	G-G	78.4	50.9	<0.001	
	C-G	0.4	0	1.000	
Omnibus LR test				<0.001	

Abbreviations: SNP = single nucleotide polymorphism; OR = odds ratio; CI = confidence interval; LR = likelihood ratio

^aModified from Huang et al [44].

suggesting that the CRTH2 gene is a strong candidate gene for asthma [44].

It is noteworthy that the field of asthma genetics has evolved in a relatively short time into a research field. If successful, the genetic approach is likely to provide a new level of understanding on the pathophysiology of the disease. It is, however, clear that there is no single major genetic risk factor for the development of asthma, and the development of the disease in an individual will depend on the interaction of several genes of moderate effect with environmental factors. Identification of specific genetic polymorphisms that influence asthma and asthma-associated phenotypes will shed light on the molecular pathways involved in these complex disorders and provide a better understanding of the pathophysiology of asthma.

References

1. Yan DC, Ou LH, Tsai TL, Huang JL. Increasing prevalence of asthma, rhinitis and atopic dermatitis among 13 to 14-year-old children in Taipei city: An ISAAC phase study. *Ann Allergy Asthma Immunol* 2005. In press.
2. Kao CC, Huang JL, Ou LS, See LC. The prevalence, severity and seasonal variation of asthma, rhinitis and eczema in Taiwan schoolchildren. *Pediatr Allergy Immunol* 2005. In press.
3. Kao CC, See LC, Yan DC, Ou LS, Huang JL. Time trends and seasonal variations in hospital admissions for childhood asthma in Taiwan from 1990 to 1998. *Asian Pacific J Allergy Immunol* 2001;19:63-8.
4. Holgate ST. Genetic and environmental interaction in allergy and asthma. *J Allergy Clin Immunol* 1999;104:1139-46.
5. Cookson W. The alliance of genes and environment in asthma and allergy. *Nature* 1999;402(6760 Suppl):B5-11.
6. Koppelman GH, Los H, Postma DS. Genetic and environment in asthma: the answer of twin studies. *Eur Respir J* 1999;13:2-4.
7. Holloway JW, Beghe B, Holgate ST. The genetic basis of atopic asthma. *Clin Exp Allergy* 1999;29:1023-32.
8. Anderson GG, Cookson WO. Recent advances in the genetics of allergy and asthma. *Mol Med Today* 1999;5:264-73.
9. Daniels SE, Bhattacharya S, James A, Leaves NI, Young A, Hill MR, et al. A genome-wide search for quantitative trait loci underlying asthma. *Nature* 1996;383:247-50.
10. Hizawa N, Freidhoff LR, Chiu YF, Ehrlich E, Luehr CA, Anderson JL, et al. Genetic regulation of *Dermatophagoides pteronyssinus*-specific IgE responsiveness: a genome-wide multipoint linkage analysis in families recruited through 2 asthmatic sibs: Collaborative Study on the Genetics of Asthma (CSGA). *J Allergy Clin Immunol* 1998;102:436-42.
11. A genome-wide search for asthma susceptibility loci in ethnically diverse populations. The Collaborative Study on the Genetics of Asthma (CSGA). *Nat Genet* 1997;15:389-92.
12. Blumenthal MM. What we know about the genetics of asthma at the beginning of the 21st century. *Clin Rev Allergy Immunol* 2002;22:11-31.
13. Hakonarson H, Bjornsdottir US, Ostermann E, Arnason T,

- Adalsteinsdottir AE, Halapi E, et al. Allelic frequencies and patterns of single-nucleotide polymorphisms in candidate genes for asthma and atopy in Iceland. *Am J Respir Crit Care Med* 2001;164:2036-44.
14. Palmer LJ, Burton PR, Faux JA, James AL, Musk AW, Cookson WO. Independent inheritance of serum immunoglobulin E concentrations and airway responsiveness. *Am J Respir Crit Care Med* 2000;161:1836-43.
15. Liggett S. β_2 -adrenergic receptor pharmacogenetics. *Am J Respir Crit Care Med* 2000;3:S197-201.
16. Liggett S. The pharmacogenetics of β_2 -adrenergic receptors: relevance to asthma. *J Allergy Clin Immunol* 2000;105:S487-92.
17. Van Eerdedewegh P, Little RD, Dupuis RD, Del Mastro RG, Falls K, Simon J, et al. Association of the ADAM33 gene with asthma and bronchial hyperresponsiveness. *Nature* 2002;418:426-30.
18. Cookson W. A new gene for asthma: would you ADAM and Eve it? *Trends Genet* 2003;19:169-72.
19. Raby BA, Silverman EK, Kwiatkowski DJ, Lange C, Lazarus R, Weiss ST. ADAM33 polymorphisms and phenotype associations in childhood asthma. *J Allergy Clin Immunol* 2004;113:1071-8.
20. Beyer K, Nickel R, Freidhoff L, Bjorksten B, Huang SK, Barnes KC, et al. Association and linkage of atopic dermatitis with chromosome 13q12-14 and 5q31-33 markers. *J Invest Dermatol* 2000;115:906-8.
21. Kimura K, Noguchi E, Shibasaki M, Arinami T, Yokouchi Y, Takeda K, et al. Linkage and association of atopic asthma to markers on chromosome 13 in the Japanese population. *Hum Mol Genet* 1999;8:1487-90.
22. Zhang Y, Leaves NI, Anderson GG, Ponting CP, Broxholme J, Holt R, et al. Positional cloning of a quantitative trait locus on chromosome 13q14 that influences immunoglobulin E levels and asthma. *Nat Genet* 2003;34:181-6.
23. Xu J, Postma DS, Howard TD, Koppelman GH, Zheng SL, Stine OC, et al. Major genes regulating total serum immunoglobulin E levels in families with asthma. *Am J Hum Genet* 2000;67:1163-73.
24. Koppelman GH, Stine OC, Xu J, Howard TD, Zheng SL, Kauffman HF, et al. Genome-wide search for atopy susceptibility genes in Dutch families with asthma. *J Allergy Clin Immunol* 2002;109:498-506.
25. Abecasis GR, Noguchi E, Heinzmann A, Traheme JA, Bhattacharya S, Leaves NI, et al. Extent and distribution of linkage disequilibrium in three genomic regions. *Am J Hum Genet* 2001;68:191-7.
26. Scanlan MJ, Gordan JD, Williamson B, Stockert E, Bander NH, Jongeneel V, et al. Antigens recognized by autologous antibody in patients with renal-cell carcinoma. *Int J Cancer* 1999;83:456-64.
27. Allen M, Heinzmann A, Noguchi E, Abecasis G, Broxholme J, Ponting CP, et al. Positional cloning of a novel gene influencing asthma from chromosome 2q14. *Nat Genet* 2003;35:258-63.
28. Sandford AJ, Changani T, Zhu S, Weir TD, Bai TR, Spinelli JJ, et al. Polymorphisms in the IL4, IL4RA and FCER1B genes and asthma severity. *J Allergy Clin Immunol* 2000;106:135-40.
29. A genome-wide search for asthma susceptibility loci in ethnically diverse populations. The Collaborative Study on the Genetics of Asthma (CSGA). *Nat Genet* 1997;15:389-92.
30. Dizier MH, Besse-Schmittler C, Guilloud-Bataille M, Annesi-Maesano I, Boussaha M, Bousquet J, et al. Genome screen for asthma and related phenotypes in the French EGEA study. *Am J Respir Crit Care Med* 2000;162:1812-8.
31. Nelson PJ, Kim HT, Manning WC, Goralski TJ, Krensky AM. Genomic organization and transcriptional regulation of the RANTES chemokine gene. *J Immunol* 1993;151:2601-12.
32. Yao TC, Kuo ML, See LC, Chen LC, Yan DC, Ou LS, et al. The RANTES promoter polymorphism: a genetic risk factor for near-fatal asthma in Chinese children. *J Allergy Clin Immunol* 2003;111:1285-92.
33. Sousa AR, Lane SJ, Nakhosteen JA, Yoshimura T, Lee TH, Poston RN. Increased expression of the monocyte chemoattractant protein-1 in bronchial tissue from asthmatic subjects. *Am J Respir Cell Mol Biol* 1994;10:142-7.
34. Campbell EM, Charo IF, Kunkel SL, Strieter RM, Boring L, Gosling J, et al. Monocyte chemoattractant protein-1 mediate cockroach allergen-induced bronchial hyperreactivity in normal but not CCR2^{-/-} mice: the role of mast cells. *J Immunol* 1999;163:2160-7.
35. Tillie-Leblond I, Hammad H, Desurmont S, Pugin J, Wallaert B, Tonnel AB, et al. CC chemokines and interleukin-5 in bronchial lavage fluid from patients with status asthmaticus. Potential implication in eosinophil recruitment. *Am J Respir Crit Care Med* 2000;162:586-92.
36. Weir TD, Mallek N, Sandford AJ, Bai TR, Awadh N, Fitzgerald JM, et al. β_2 -Adrenergic receptor haplotypes in mild, moderate and fatal/near fatal asthma. *Am J Respir Crit Care Med* 1998;158:787-91.
37. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. *Immunity* 2000;12:121-7.
38. Yao TC, Wu KC, Chung HT, Shaw CK, Kuo ML, Wu CJ, et al. MCP-1 gene regulatory region polymorphism in Chinese children with mild, moderate and near-fatal asthma. *Allergy* 2004;59:436-41.
39. Nagata K, Hirai H, Tanaka K, Ogawa K, Aso T, Sugamura K, et al. CRTH2, an orphan receptor of T-helper-2-cells, is expressed on basophils and eosinophils and responds to mast cell-derived factor(s). *FEBS Lett* 1999;459:195-9.

40. Nagata K, Tanaka K, Ogawa K, Kemmotsu K, Imai T, Yoshie O, et al. Selective expression of a novel surface molecule by human Th2 cells in vivo. *J Immunol* 1999;162:1278-86.
41. Cosmi L, Annunziato F, Galli MIG, Maggi RME, Nagata K, Romagnani S. CRTH2 is the most reliable marker for the detection of circulating human type 2 Th and type 2 T cytotoxic cells in health and disease. *Eur J Immunol* 2000;30:2972-9.
42. Hirai H, Tanaka K, Yoshie O, Ogawa K, Kenmotsu K, Takamori Y, et al. Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. *J Exp Med* 2001; 193:255-61.
43. Hsu SC, Chen LC, Kuo ML, Huang JL, Huang SK. Novel SNPs in a candidate gene, CRTH2, for allergic diseases. *Genes Immun* 2002;3:114-6.
44. Huang JL, Gao PS, Mathias RA, Yao TC, Chen LC, Kuo ML, et al. Sequence variants of the gene encoding chemoattractant receptor expressed on Th2 cells (CRTH2) are associated with asthma and differentially influence mRNA stability. *Hum Mol Genet* 2004;13:2691-7.